KNSAKiniksa Pharmaceuticals International, plc
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +44% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How KNSA is trading
Kiniksa Pharmaceuticals International, plc is +125% over the past year while the S&P 500 is +18%: 107 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +44%
vs 200-day average · a clear uptrend
- RSI (14)
- 58
RSI (14) · neutral
- Below its 52-week high
- 1.3%
Below its 52-week high
Details›
- Last close2026-10-09
- $79.76
- 1 monthS&P 500 +2.7%
- +4.1%
- 1 yearS&P 500 +18%
- +125%
- 5 yearsS&P 500 +88%
- +557%
- vs 50-day average$77.28
- +3.2%
- 52-week high
- $80.83
- 52-week low
- $35.51
- Annualised volatility
- 49%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$299K
| Year | Return |
|---|---|
| 2026 (year to date) | +93% |
| 2025 | +109% |
| 2024 | +13% |
| 2023 | +17% |
| 2022 | +27% |
| 2021 | −33% |
| 2020 | +60% |
| 2019 | −61% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 4 of 8 | +0.59% |
| Feb | 8 | 6 of 8 | +4.7% |
| Mar | 8 | 3 of 8 | −4.2% |
| Apr | 8 | 3 of 8 | +2.8% |
| May | 8 | 5 of 8 | −0.81% |
| Jun | 9 | 7 of 9 | +6.6% |
| Jul | 9 | 6 of 9 | +9.1% |
| Aug | 9 | 4 of 9 | +2.8% |
| Sep | 9 | 4 of 9 | +0.44% |
| Oct | 9 | 2 of 9 | −8.9% |
| Nov | 8 | 7 of 8 | +19% |
| Dec | 8 | 4 of 8 | +2.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore